Bicycle to cut 30% of staff after cancer drug's regulatory setback
Bicycle Therapeutics因其癌症药物遭遇监管受挫，将裁员30%

Bicycle Therapeutics plans to cut its operating expenses in half to preserve cash, laying off about 30% of its staff and ending work on two early trials, the company announced.
Bicycle Therapeutics宣布将把运营开支削减一半以保留现金，计划裁员约30%，并终止两项早期临床试验的相关工作。